Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II Study of Pirfenidone to Prevent Radiation-Induced Lung Injury in Neoadjuvant Chemotherapy + Immunotherapy + Radiotherapy for NSCLC
ChiCTR2500095621Phase 2Not yet recruiting
- Sponsor
- The Second Affiliated Hospital of Guizhou Medical University
- Start
- Jan 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pirfenidone in non-small cell lung cancer (NSCLC), sponsored by The Second Affiliated Hospital of Guizhou Medical University. Primary endpoints: Incidence of grade ≥2 radiation-induced lung injury and Progression-free survival. Planned start Jan 2025; status: not yet recruiting.
02
Drugs
pirfenidone
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on ChiCTR2500095621.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500095621.